INHIBIKASE THERAPEUTICS INC (IKT) Forecast, Price Target & Analyst Ratings
NASDAQ:IKT • US45719W2052
1.88 USD
-0.01 (-0.53%)
At close: Mar 6, 2026
1.9 USD
+0.02 (+1.06%)
After Hours: 3/6/2026, 8:26:36 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INHIBIKASE THERAPEUTICS INC (IKT).
Forecast Snapshot
Consensus Price Target
$6.12
+ 225.53% Upside
Next Earnings Forecast
Release DateMar 25, 2026
PeriodQ4 / 2025
EPS Estimate-$0.11
Revenue Estimate
ChartMill Buy Consensus
83.64%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$6.12
Upside
+ 225.53%
From current price of $1.88 to mean target of $6.12, Based on 11 analyst forecasts
Low
$3.03
Median
$6.12
High
$8.40
Price Target Revisions
1 Month
0.00%
3 Months
-25.00%
Price Target Summary
11 analysts have analysed IKT and the average price target is 6.12 USD. This implies a price increase of 225.53% is expected in the next year compared to the current price of 1.88.
The average price target has been revised downward by 25% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
83.64%
IKT was analyzed by 11 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about IKT.
In the previous month the buy percentage consensus was at a similar level.
IKT was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-04 | Ladenburg Thalmann | Initiate | Buy |
| 2026-01-21 | B of A Securities | Initiate | Buy |
| 2025-12-11 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-03-28 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-02-12 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-11-08 | Jefferies | Initiate | Buy |
| 2024-10-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-18 | HC Wainwright & Co. | Initiate | Buy |
| 2022-11-16 | JonesTrading | Downgrade | Buy -> Hold |
| 2021-07-15 | JonesTrading | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 25, 2026
PeriodQ4 / 2025
EPS Estimate-$0.11
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q77.11%
Number of Analysts7
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
9.34%
Next Earnings Summary
IKT is expected to report earnings on 3/25/2026. The consensus EPS estimate for the next earnings is -0.11 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.1M 342.86% | 120K -96.13% | 260.5K 117.08% | -100.00% | 288.567K | 404K 40.00% | ||
| EBITDA YoY % growth | N/A | -18.12M | -19.912M -9.89% | N/A -43.44% | -51.106M -78.93% | -53.772M -5.22% | N/A | |
| EBIT YoY % growth | -14.77M -423.76% | -18.13M -22.75% | -20.09M -10.81% | -22.086M -42.31% | -52.563M -83.86% | -70.387M -33.91% | -82.699M -17.49% | |
| Operating Margin | -476.45% | -15,108.33% | -7,712.02% | N/A | N/A | -24,391.91% | -20,469.96% | |
| EPS YoY % growth | N/A | -4.32 8.61% | -3.57 17.36% | -0.91 28.85% | -0.51 79.78% | -0.54 -4.78% | -0.56 -4.34% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.11 77.11% | -0.11 34.65% | -0.13 -14.77% | -0.13 -2.94% | -0.16 -44.12% | -0.19 -72.73% | -0.20 -60.00% | -0.21 -58.49% | -0.21 -28.57% |
| Revenue Q2Q % growth | 757.5K | -100.00% | |||||||
| EBITDA Q2Q % growth | -12.534M 2.85% | -13.473M -87.51% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -13.595M -5.16% | -14.949M -107.68% | -16.566M -52.93% | -17.87M -39.96% | -18.75M -37.92% | -18.382M -22.97% | -19.392M -17.06% | -20.503M -14.73% | -20.503M -9.35% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
21.17%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
INHIBIKASE THERAPEUTICS INC / IKT Forecast FAQ
What is the price target for IKT stock?
11 analysts have analysed IKT and the average price target is 6.12 USD. This implies a price increase of 225.53% is expected in the next year compared to the current price of 1.88.
Can you provide the upcoming earnings date for INHIBIKASE THERAPEUTICS INC?
INHIBIKASE THERAPEUTICS INC (IKT) will report earnings on 2026-03-25, after the market close.
What are the consensus estimates for IKT stock next earnings?
The consensus EPS estimate for the next earnings of INHIBIKASE THERAPEUTICS INC (IKT) is -0.11 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for INHIBIKASE THERAPEUTICS INC (IKT) stock?
The consensus rating for INHIBIKASE THERAPEUTICS INC (IKT) is 83.6364 / 100 . This indicates that analysts generally have a positive outlook on the stock.